Moderna, Inc. (MRNA) vs NOVAVAX INC (NVAX)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | MRNA | NVAX |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $1.94B | $1.12B |
| Revenue growth (YoY) | ▼ 39.9% | ▲ 64.7% |
| Net income | -$2.82B | $440.3M |
| Gross margin | 55.3% | 93.5% |
| Diluted EPS | $-7.26 | $2.58 |
| Insider net (6 mo) | +421.8K sh • 11 sells • 0 buys | +122.8K sh • 0 sells • 0 buys |
| Institutional owners | 43 | 38 |
| Institutional value held | $19.58B | $819.92M |
| Next earnings (est.) | Around Nov 5, 2026 | Around Nov 5, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About Moderna, Inc. (MRNA)
Moderna is a biotechnology company and pioneer in mRNA medicine, using its integrated mRNA, lipid nanoparticle (LNP) delivery, and manufacturing platform to develop vaccines and therapeutics across infectious disease, oncology, and rare disease. Read more →
About NOVAVAX INC (NVAX)
Novavax, Inc., a Delaware corporation founded in 1987 and headquartered in Gaithersburg, Maryland, is a biotechnology company that discovers, develops and commercializes vaccines to prevent serious infectious diseases. Read more →
Source: SEC EDGAR.